Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 4143

Sort by

Sort Order Select

Journal Articles

Exploring the pathways to chronic lymphocytic leukemia

Freda K. Stevenson, Francesco Forconi, Thomas J. Kipps

Blood (2021) 138 (10): 827–835.

https://doi.org/10.1182/blood.2020010029

Published: 2021

Journal Articles

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

Blood (2021) 137 (18): 2463–2480.

https://doi.org/10.1182/blood.2019004547

Published: 2021

Includes: Supplemental data

Journal Articles

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Yu Jia Shen, Yuji Mishima, Jiantao Shi, Romanos Sklavenitis-Pistofidis, Robert A. Redd, Michele Moschetta, Salomon Manier, Aldo M. Roccaro, Antonio Sacco, Yu-Tzu Tai, Francois Mercier, Yawara Kawano, Nang Kham Su, Brianna Berrios, John G. Doench, David E. Root, Franziska Michor, David T. Scadden, Irene M. Ghobrial

Blood (2021) 137 (17): 2360–2372.

https://doi.org/10.1182/blood.2020005885

Published: 2021

Includes: Supplemental data

Journal Articles

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Blood (2021) 137 (11): 1491–1502.

https://doi.org/10.1182/blood.2020007245

Published: 2021

Includes: Supplemental data

Journal Articles

Immune escape mechanisms for TCRLBCL

Wing C. Chan

Blood (2021) 137 (10): 1274–1276.

https://doi.org/10.1182/blood.2020008766

Published: 2021

Journal Articles

Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model

Manuel J. Feinauer, Stefan W. Schneider, Anna S. Berghoff, Jose Ramon Robador, Cedric Tehranian, Matthia A. Karreman, Varun Venkataramani, Gergely Solecki, Julia Katharina Grosch, Katharina Gunkel, Bogdana Kovalchuk, Frank Thomas Mayer, Manuel Fischer, Michael O. Breckwoldt, Maik Brune, Yannick Schwab, Wolfgang Wick, Alexander T. Bauer, Frank Winkler

Blood (2021) 137 (9): 1219–1232.

https://doi.org/10.1182/blood.2020005710

Published: 2021

Includes: Supplemental data

Journal Articles

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Damien Roos-Weil, Brian Giacopelli, Marine Armand, Véronique Della-Valle, Hussein Ghamlouch, Camille Decaudin, Marlen Metzner, Junyan Lu, Magali Le Garff-Tavernier, Véronique Leblond, Paresh Vyas, Thorsten Zenz, Florence Nguyen-Khac, Olivier A. Bernard, Christopher C. Oakes

Blood (2020) 136 (5): 585–595.

https://doi.org/10.1182/blood.2020005081

Published: 2020

Includes: Supplemental data

Journal Articles

Platelet glycoprotein VI promotes metastasis through interaction with cancer cell–derived galectin-3

Elmina Mammadova-Bach, Jesus Gil-Pulido, Edita Sarukhanyan, Philipp Burkard, Sergey Shityakov, Charlotte Schonhart, David Stegner, Katharina Remer, Paquita Nurden, Alan T. Nurden, Thomas Dandekar, Laszlo Nehez, Magdolna Dank, Attila Braun, Diego Mezzano, Scott I. Abrams, Bernhard Nieswandt

Blood (2020) 135 (14): 1146–1160.

https://doi.org/10.1182/blood.2019002649

Published: 2020

Includes: Supplemental data

Journal Articles

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution

Mariette Odabashian, Emanuela Carlotti, Shamzah Araf, Jessica Okosun, Filomena Spada, John G. Gribben, Francesco Forconi, Freda K. Stevenson, Mariarita Calaminici, Sergey Krysov

Blood (2020) 135 (11): 834–844.

https://doi.org/10.1182/blood.2019002279

Published: 2020

Includes: Supplemental data

Journal Articles

Supercharging your CAR

Sneha Ramakrishna, Kara L. Davis

Blood (2020) 135 (9): 593–594.

https://doi.org/10.1182/blood.2019004469

Published: 2020

Journal Articles

Carbon Dots As a Potential Therapeutic Agent for Anemia Treatment in Malignancies

Yuanlin Xu, Boyang Wang, Huan Zhang, Xiaoli Qu, Mingming Zhang, Xiuli An, Siyu Lu, Shijie Zhang

Blood (2019) 134 (Supplement_1): 941.

https://doi.org/10.1182/blood-2019-130971

Published: 2019

Journal Articles

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Pablo Domizi, PhD, Astraea Jager, BS, Jolanda Sarno, PhD, Charles G. Mullighan, MBBS, MD, Stephan Grupp, MD PhD, Elena Sotillo, PhD, David M. Barrett, Kara L. Davis, DO

Blood (2019) 134 (Supplement_1): 749.

https://doi.org/10.1182/blood-2019-128883

Published: 2019

Journal Articles

Efficacy and Safety of Azacitidine (AZA) in Combination with the Anti-PD-L1 Durvalumab (durva) for the Front-Line Treatment of Older Patients (pts) with Acute Myeloid Leukemia (AML) Who Are Unfit for Intensive Chemotherapy (IC) and Pts with Higher-Risk Myelodysplastic Syndromes (HR-MDS): Results from a Large, International, Randomized Phase 2 Study

Amer M. Zeidan, MBBS, MHS, James Cavenagh, Maria Teresa Voso, David Taussig, Mar Tormo, Isaac Boss, Wilbert B. Copeland, Vanessa E. Gray, Alessandro Previtali, Tim O'Connor, Shelonitda Rose, CL Beach, Lewis R. Silverman

Blood (2019) 134 (Supplement_1): 829.

https://doi.org/10.1182/blood-2019-122896

Published: 2019

Journal Articles

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

Ivana Gojo, MD, Robert K. Stuart, MD, Jonathan Webster, MD, Amanda Blackford, MS, Juan Carlos Varela, MD PhD, Jillian Morrow, RN, Amy E. DeZern, MD, Matthew C Foster, MD, Mark J. Levis, MD, Catherine C. Coombs, MD, Gabrielle T. Prince, MD, B. Douglas Smith, MD, Hendrik W. Van Deventer, MD, Katarzyna Jamieson, MD, Ravi Varadhan, PhD, Benjamin G. Vincent, MD, Jonathan S Serody, MD, Leo Luznik, MD, Joshua F Zeidner, MD

Blood (2019) 134 (Supplement_1): 832.

https://doi.org/10.1182/blood-2019-127345

Published: 2019

Journal Articles

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

Blood (2019) 134 (Supplement_1): 877.

https://doi.org/10.1182/blood-2019-131255

Published: 2019

Journal Articles

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

Lei Xiao, PhD

Blood (2019) 134 (Supplement_1): 4631.

https://doi.org/10.1182/blood-2019-130703

Published: 2019

Journal Articles

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Daisuke Ogiya, MD PhD, Lisa Müller, Sigitas J Verselis, PhD, Heiner Schaal, PhD, Ivane Abiatari, MD, Ana M Stenstrom, Catherine A Nicholas, John F Daley, Michael P. Chu, David M. Dorfman, MD PhD, Linda M. Pilarski, PhD, Teru Hideshima, MD PhD, Kenneth C. Anderson, MD, Sophia Adamia, PhD

Blood (2019) 134 (Supplement_1): 1804.

https://doi.org/10.1182/blood-2019-131775

Published: 2019

Journal Articles

Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

Deeksha Vishwamitra, Christine Mantis, PhD, Dipica Haribhai, PhD, Tamar Uziel, PhD, Joel D. Leverson, PhD, James M. Pauff, MD PhD, Orlando F. Bueno, MD PhD, Paulo C. Maciag, MD PhD, Jeremy A. Ross, PhD

Blood (2019) 134 (Supplement_1): 1896.

https://doi.org/10.1182/blood-2019-128672

Published: 2019

Journal Articles

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Fatiha Rachedi, Kimiko Koiwai, Nadia Gaudel-Dedieu, Bernard Sebastien, Hoai-Thu Thai, Raouf El-Cheikh, Claire Brillac, Jean Baptiste Fau, Laurent Nguyen, Li Liu, Frank Campana, MD, Helgi van de Velde, MD PhD, Christine Veyrat-Follet, Dorothee Semiond, PhD PharmD

Blood (2019) 134 (Supplement_1): 1897.

https://doi.org/10.1182/blood-2019-128875

Published: 2019

Journal Articles

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Shunichiro Yasuda, MD, Satoru Aoyama, MD, Ryoto Yoshimoto, Student, Watanabe Daisuke, MD, Hiroki Akiyama, MD, PhD, Yoshihiro Umezawa, MD, PhD, Ayako Nogami, MD PhD BPharm, Kouhei Yamamoto, Takeo Fujiwara, MD, Yoko Edahiro, MD PhD, Marito Araki, PhD, Norio Komatsu, MD PhD, Tetsuya Fukuda, MD PhD, Ayako Arai, MD PhD, Osamu Miura, MD, PhD, Norihiko Kawamata

Blood (2019) 134 (Supplement_1): 1690.

https://doi.org/10.1182/blood-2019-122652

Published: 2019

NARROW

Exploring the pathways to chronic lymphocytic leukemia

Single-cell RNA-seq reveals developmental plasticity with coexisting oncogenic states and immune evasion programs in ETP-ALL

Progression signature underlies clonal evolution and dissemination of multiple myeloma

Frequent genetic alterations in immune checkpoint–related genes in intravascular large B-cell lymphoma

Immune escape mechanisms for TCRLBCL

Local blood coagulation drives cancer cell arrest and brain metastasis in a mouse model

Identification of 2 DNA methylation subtypes of Waldenström macroglobulinemia with plasma and memory B-cell features

Platelet glycoprotein VI promotes metastasis through interaction with cancer cell–derived galectin-3

IGHV sequencing reveals acquired N-glycosylation sites as a clonal and stable event during follicular lymphoma evolution

Supercharging your CAR

Carbon Dots As a Potential Therapeutic Agent for Anemia Treatment in Malignancies

Prediction of Patients at Risk of CD19 Neg Relapse Following CD19-Directed CAR T Cell Therapy in B Cell Precursor Acute Lymphoblastic Leukemia

Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine (AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients

The Folate Cycle Enzyme MTHFR Is a Critical Regulator of Cell Response to MYC-Targeting Therapies

New Generation Chimeric Antigen Receptor T-Cell Therapy (CoupledCAR) Induces High Rate Remissions in Solid Tumor

Aberrant RHAMM Splicing in Multiple Myeloma (MM) and Its Implications for Immunotherapy

Immune Profiling of Relapsed/Refractory Multiple Myeloma Patients Treated with Venetoclax in Combination with Dexamethasone (VenDex), Daratumumab and Dexamethasone (VenDd), and Daratumumab, Bortezomib and Dexamethasone (VenDVd)

Exposure-Response Analyses and Disease Modeling for Selection and Confirmation of Optimal Dosing Regimen of Isatuximab in Combination Treatment in Patients with Multiple Myeloma

Overexpression of MPL Causes Ruxolitinib-Resistance in Myeloproliferative Neoplasms with Calreticulin Frame-Shift Mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only